^
Association details:
| Biomarker: | ALK rearrangement |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) + YHO-1701 (STAT3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis
Published date:
02/28/2022
Excerpt:
STAT3 inhibition effectively suppressed the adaptive survival of ALK-rearranged lung cancer cells by enhancing ALK inhibition-induced apoptosis…. In xenograft study, the combination of YHO-1701 (STAT3 inhibitor) and alectinib significantly suppressed tumor regrowth after treatment cessation with near tumor remission compared with alectinib alone. Hence, this study provides new insights into combined therapeutic strategies for patients with ALK-rearranged lung cancer.
DOI:
10.1038/s41698-022-00254-y
